Ocanto A, Torres L, Couñago F. Current status of anaplastic thyroid carcinoma. World J Clin Oncol 2024; 15(6): 684-686 [DOI: 10.5306/wjco.v15.i6.684]
Corresponding Author of This Article
Abrahams Ocanto, MD, Doctor, Department of Radiation Oncology, San Francisco de Asís University Hospital, 28 Joaquín Costa St, Genesis Care, Madrid 28002, Spain. abrahams.ocanto@genesiscare.es
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 24, 2024; 15(6): 684-686 Published online Jun 24, 2024. doi: 10.5306/wjco.v15.i6.684
Current status of anaplastic thyroid carcinoma
Abrahams Ocanto, Lisselott Torres, Felipe Couñago
Abrahams Ocanto, Lisselott Torres, Felipe Couñago, Department of Radiation Oncology, San Francisco de Asís University Hospital, Genesis Care, Madrid 28002, Spain
Abrahams Ocanto, Lisselott Torres, Felipe Couñago, Department of Radiation Oncology, Vithas La Milagrosa University Hospital, Genesis Care, Madrid 28010, Spain
Author contributions: Ocanto A, Torres L and Couñago F contributed to this paper; Ocanto A, Torres L and Couñago F designed the overall concept and outline of the manuscript; Couñago F contributed to the discussion and design of the manuscript; Ocanto A, Torres L and Couñago F contributed to the writing, and editing the manuscript and review of literature.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abrahams Ocanto, MD, Doctor, Department of Radiation Oncology, San Francisco de Asís University Hospital, 28 Joaquín Costa St, Genesis Care, Madrid 28002, Spain. abrahams.ocanto@genesiscare.es
Received: January 11, 2024 Revised: April 21, 2024 Accepted: April 25, 2024 Published online: June 24, 2024 Processing time: 165 Days and 2.1 Hours
Abstract
In this editorial we comment on the article by Pavlidis et al, published in the recent issue of the World Journal of Oncology. We focus on the recent contributions in the management of anaplastic thyroid carcinoma, highlighting the importance of surgery and radiotherapy as first line therapies in its management and the introduction of new systemic therapies beyond chemotherapy, focused on molecular alterations, an essential step in the diagnosis and included in clinical guidelines for the selection of the ideal treatment. In contrast to other neoplasms, immunotherapy, is still beginning in studies of this pathology with encouraging results. Therefore, multimodal management of the pathology together with new drugs seems to be the logical step to increase the survival of this neoplasm.
Core Tip: Anaplastic thyroid carcinoma is an entity with high mortality despite the combination of treatments, today molecular analysis opens the door to new drugs that impact survival in a positive way when used in a multimodal form.
